Beijing Luzhu Biotechnology Past Earnings Performance
Past criteria checks 0/6
Beijing Luzhu Biotechnology has been growing earnings at an average annual rate of 65.6%, while the Biotechs industry saw earnings growing at 11.7% annually.
Key information
65.6%
Earnings growth rate
74.8%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | n/a |
Return on equity | -24.4% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beijing Luzhu Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -249 | 87 | 173 |
30 Sep 23 | 0 | -201 | 85 | 121 |
30 Jun 23 | 0 | -152 | 82 | 69 |
31 Mar 23 | 0 | -439 | 84 | 80 |
31 Dec 22 | 0 | -725 | 86 | 91 |
Quality Earnings: 2480 is currently unprofitable.
Growing Profit Margin: 2480 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2480's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2480's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2480 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2480 has a negative Return on Equity (-24.43%), as it is currently unprofitable.